ライフサイエンスコーパス: total hip

1 ut not less than -4.0 at the lumbar spine or total hip.

2 ent in BMD of 2.2% +/- 0.9% (P < .05) at the total hip.

3 ly associated with BMC in the whole body and total hip.

4 spine; and -0.05, 95% CI -0.07 to -0.03 for total hip.

5 2 versus 0.913 +/- 0.04 g/cm2; p = 0.01) and total hip (0.648 +/- 0.04 versus 0.811 +/- 0.04 g/cm2; p

6 e, +0.7 +/- 1.6; femoral neck, -0.1 +/- 1.1; total hip, 0.0 +/- 1.1).

7 e-by-group interaction: lumbar spine, 0.002; total hip, 0.03; whole body, 0.03).

8 h the tamoxifen group (lumbar spine, +2.77%; total hip, +0.74%).

9 ine, -0.2 +/- 1.6; femoral neck, -0.6 +/- 1; total hip, -0.6 +/- 1.1; matched, P < 0.01 at all sites)

10 e, -0.4 +/- 1.6; femoral neck, -0.7 +/- 1.1; total hip, -0.7 +/- 1.1).

11 femoral neck (2.39%; 95% CI: 3.61%, 1.17%), total hip (1.51%; 95% CI: 2.45%, 0.60%), and whole body

12 normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.0

13 -1.70 +/- 0.25%; spine, -3.03 +/- 0.72%; and total hip, -1.87 +/- 0.60%.

14 ith mean (SD) increases of 5.9% (3.8) at the total hip, 10.4% (5.4) at the posteroanterior lumbar spi

15 0.5%) and F52 (lumbar spine, -6.2 +/- 0.9%; total hip, -10.3 +/- 1.4%; whole body, -3.2 +/- 0.6%).

16 = 0.001): NPNL (lumbar spine, -7.5 +/- 0.7%; total hip, -10.5 +/- 1.0%; whole body, -3.6 +/- 0.5%) an

17 r 5 years resulted in declines in BMD at the total hip (-2.4%; 95% confidence interval [CI], -2.9% to

18 ncreases of 2.6% for the femoral neck; 3.6%, total hip; 2.8%, spine; and 1.2%, total body.

19 For the total hip, 3 year mean BMD change for women receiving an

20 -3.4] vs -1.2% [-1.7 to -0.7], p<0.0001) and total hip (-4.0% [-4.4 to -3.6] vs -1.8% [-2.1 to -1.4],

21 line to 5 years in lumbar spine (-6.08%) and total hip (-7.24%) compared with the tamoxifen group (lu

22 seline by 16.5% at the lumbar spine, 7.4% at total hip, 7.1% at femoral neck, and 2.3% at one-third r

23 seline by 21.7% at the lumbar spine, 9.2% at total hip, 9.0% at femoral neck, and 2.7% at the one-thi

24 For the total hip, a small 0.3% (-0.9 to 1.5) increase was noted

25 +/- 1.0% change from baseline; P < 0.05) and total hip aBMD (2.6% +/- 1.0% vs. -2.4% +/- 1.0% change;

26 t for age, body mass index, knee height, and total hip aBMD.

27 reduced BMD at the lumbar spine (17 +/- 3%), total hip and femoral neck (24 +/- 3% and 20 +/- 4%, res

28 265 black women and 75 black men to predict total hip and femoral neck BMD or changes in BMD.

29 m supplementation reduced bone loss from the total hip and femoral neck in those who consumed <1.5 se

30 rge increases in bone mineral density at the total hip and femoral neck, as well as transitory increa

31 BMD of the lumbar spine, total hip and hip subregions, as measured by QCT, but on

32 luded changes in bone mineral density at the total hip and in markers of bone turnover, the time to c

33 BMD of the total hip and its subregions was measured using dual ene

34 Clinical improvement projects included total hip and knee joint replacement, hospitalist labora

35 made to physicians by five manufacturers of total hip and knee prostheses in 2007.

36 ompletely eliminated for patients undergoing total hip and knee replacement at the Richard L.

37 More than 70% of total hip and knee replacements are for osteoarthritis.

38 Center, Indianapolis, Indiana, revealed that total hip and knee replacements incurred $1.4 million in

39 y and completely eliminating non-VA care for total hip and knee replacements while increasing total j

40 Bone mineral density was measured at the total hip and lumbar spine using dual-energy x-ray absor

41 Total hip and spine areal BMD were determined with dual-

42 -related decline in bone density at both the total hip and the trochanter of 0.00044 g per square cen

43 to L4) and lateral lumbar (L2 to L4) spine, total hip (and subregions), and radius bone densities we

44 Total hip (and subregions), spine, and total-body BMDs w

45 ay absorptiometry, we compared lumbar spine, total hip, and femoral neck bone mineral density (BMD) i

46 HA-DLS, BMD at the femoral neck, trochanter, total hip, and lumbar spine (L2-L4) was associated with

47 nsity (BMD) at the femoral neck, trochanter, total hip, and lumbar spine (L2-L4) was measured by usin

48 steoporosis or osteopenia at the trochanter, total hip, and lumbar spine (L2-L4) were lower by 14% (O

49 are -2.6 at the lumbar spine and -1.9 at the total hip, and spine imaging shows several vertebral end

50 the trochanter, and 1.8+/-0.4 percent in the total hip, and the mean trabecular bone mineral density

51 crease in bone mineral density at the spine, total hip, and total body has been reported with raloxif

52 the mean percentage change from baseline in total hip areal BMD was 2.6% (95% CI 2.2 to 3.0) in the

53 repair surgery (fracture groups, n = 33) or total hip arthroplasty (nonfracture groups, n = 17).

54 ween such parameters and the 19-year risk of total hip arthroplasty (THA) for end-stage OA.

55 ace narrowing in the contralateral hip after total hip arthroplasty (THA) for osteoarthritis (OA) and

56 utcome and predictors of prognosis following total hip arthroplasty (THA) for osteoarthritis (OA).

57 Thirty-day readmission to hospital after total hip arthroplasty (THA) has significant direct cost

58 role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial.

59 A total of 108 men and women scheduled for total hip arthroplasty (THA) or total knee arthroplasty

60 es on hospitals' SSI rates following primary total hip arthroplasty (THA) or total knee arthroplasty

61 urce of dislocation and aseptic loosening in total hip arthroplasty (THA).

62 atient increased from 1.0 to 2.0 for primary total hip arthroplasty and 1.1 to 2.3 for revision (P <

63 e Part A beneficiaries who underwent primary total hip arthroplasty and 348,596 who underwent revisio

64 risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital

65 in patients older than 10 years, 19 required total hip arthroplasty and none improved.

66 the results of both cemented and cementless total hip arthroplasty at mid- to long-term follow-up.

67 Modification codes for primary and revision total hip arthroplasty between 1991 and 2008.

68 Total hip arthroplasty continues to be an extremely succ

69 alloys have been used in dental implants and total hip arthroplasty due to their excellent biocompati

70 All subjects had undergone total hip arthroplasty for idiopathic arthritis, and the

71 nd any new radiographic finding of hip OA or total hip arthroplasty for OA (OR 1.71, 95% CI 1.16-2.52

72 sed from 74.1 to 75.1 years and for revision total hip arthroplasty from 75.8 to 77.3 years (P < .001

73 the mean age for patients undergoing primary total hip arthroplasty increased from 74.1 to 75.1 years

74 Total hip arthroplasty is a common surgical procedure bu

75 Total hip arthroplasty is a cost-effective surgical proc

76 hat symptomatic venous thromboembolism after total hip arthroplasty most commonly develops after the

77 The proportion of primary total hip arthroplasty patients discharged home declined

78 Some allograft bone donated from primary total hip arthroplasty recipients must be discarded or t

79 y" to a low of 0.005 for "Procedure-Targeted Total Hip Arthroplasty Surgical Site Infection." General

80 2509 patients scheduled to undergo elective total hip arthroplasty were randomly assigned, stratifie

81 opic cholecystectomy, partial colectomy, and total hip arthroplasty were used.

82 pitalization (range: 61% for TURP to 88% for total hip arthroplasty), and are thus missed by the ProP

83 In patients who underwent total hip arthroplasty, a body-mass index of 25 or great

84 nal aortic aneurysm (AAA) repair, colectomy, total hip arthroplasty, and pancreatectomy.

85 For primary total hip arthroplasty, mean hospital LOS decreased from

86 For revision total hip arthroplasty, similar trends were observed in

87 hroplasty and 348,596 who underwent revision total hip arthroplasty.

88 g symptomatic events, in patients undergoing total hip arthroplasty.

89 th clonidine was used in patients undergoing total hip arthroplasty.

90 or thromboembolism within three months after total hip arthroplasty.

91 in 185 patients who had previously undergone total hip arthroplasty.

92 asured by QCT, but only the lumbar spine and total hip, as measured by DXA, were significantly associ

93 ne mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 mont

94 ineral density (BMD) in the lumbar spine and total hip between patients treated with exemestane and p

95 2.1%; P = .0109) and a numerical decrease in total hip BMD (-0.4%; P = .5988).

96 nant RFVOL was independently associated with Total Hip BMD (p < 0.001).

97 sion score was significantly correlated with total hip BMD (r=-0.33, P<0.0001), but not with lumbar s

98 For men, the correlation between total hip BMD and dairy calcium intake after adjustment

99 Conclusion: Treatment-related increases in total hip BMD are associated with reduced fracture risk

100 n a significant increase in lumbar spine and total hip BMD compared with A + P treatment (2.2% v -1.8

101 ability, women with a detectable decrease in total hip BMD compared with stable BMD had an absolute i

102 Similarly, total hip BMD declined by 0.8% at 6 months and 2.6% at 1

103 Women who had larger increases in total hip BMD during the first 12 months had a lower inc

104 3.2% of women with increases of > or =3% in total hip BMD experienced new vertebral fractures, where

105 incorporate bone mineral density (BMD), with total hip BMD in 10,418 WHI participants who had both de

106 Total hip BMD increased 3.7% after 3 years of treatment

107 the lumbar spine BMD increased by 7.2%, and total hip BMD increased by 2.1% (P < 0.01 for both).

108 In the H stratum, lumbar spine and total hip BMD increased significantly (3.0%; P = .0006;

109 ients with serial bone density examinations, total hip BMD increased transiently in women with parath

110 nd soluble CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell sen

111 cumulative oral glucocorticoid dose, neither total hip BMD nor lumbar spine BMD was significantly ass

112 total hip BMD, and 21% had either decreased total hip BMD or no change.

113 n kg/m(2)) >27] postmenopausal women, with a total hip BMD t score less than -2.0.

114 al fracture ranged from 56% among women with total hip BMD T score of -2.5 or less and a prevalent ve

115 ular volumetric BMD, cortical thickness, and total hip BMD those with stage 0-2 fibrosis.

116 cture in women with a detectable increase in total hip BMD was 1.3% (CI, 0.4% to 2.2%) and 2.6% (CI,

117 ian (interquartile range) percent decline in total hip BMD was greater in those with high- compared t

118 For women, each 1-SD reduction in total hip BMD was similarly associated with an increased

119 At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium

120 Lumbar spine and total hip BMD were assessed at baseline and after 1, 2,

121 al fracture (odds ratio per 1 SD decrease in total hip BMD, 1.78 [95% confidence interval, 1.58-2.00]

122 of participants had increases of > or =3% in total hip BMD, and 21% had either decreased total hip BM

123 osumab (2.1% [3.8], p=0.0238) groups, as did total-hip BMD (combination, 4.9% [2.9]; teriparatide, 0.

124 otal-body (P < 0.045), spine (P = 0.03), and total-hip BMDs (P = 0.029).

125 y endpoints were changes in lumbar spine and total hip bone mineral densities (BMDs); secondary endpo

126 he primary endpoint was percentage change in total hip bone mineral density (BMD) from baseline to we

127 Lumbar spine and total hip bone mineral density (BMD) were assessed at ba

128 The primary outcome measure was total hip bone mineral density (BMD); secondary measures

129 mean percentage changes in lumbar spine and total hip bone mineral density at week 48, assessed by d

130 the bone mineral density secondary outcomes, total hip bone mineral density increased more in the ter

131 Total hip bone mineral density loss was similarly greate

132 pecific effect of weight change on change in total hip bone mineral density was evaluated over 4 year

133 36-month differences in percentage change in total hip bone mineral density were 0.79 percentage poin

134 Adjustment for total-hip bone mineral density eliminated the elevated r

135 - 0.8% at the spine and 2.8% +/- 0.5% at the total hip (both P < .001).

136 BMD increased at the total hip by 2.0% and 1.2%, respectively.

137 density was measured at the lumbar spine and total hip by dual-energy X-ray absorptiometry.

138 BMD of the total hip decreased by 1.9% +/- 0.7% in men assigned to

139 ant increases in bone mineral density at the total hip, femoral neck, and distal third of the radius

140 e mineral density (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius.

141 s with fracture had lower aBMD at the spine, total hip, femoral neck, and the ultradistal radius, the

142 s in bone mineral density of the total body, total hip, femoral neck, and trabecular bone of the lumb

143 an areal BMD T score of -2.5 or lower at the total hip, femoral neck, or lumbar spine; and a history

144 Bone mass at total hip, femoral neck, spine (L2-4), and whole body (W

145 change of BMD at 2 years in lumbar spine and total hip for both groups.

146 n BMD at the lumbar spine, femoral neck, and total hip from the end of year 1 (mean change -5.1%, -9.

147 crease]), as did bone mineral density at the total hip (grams per square centimeter; 1.010 to 0.996 [

148 At 12 months, bone mineral density at the total hip had increased more in the teriparatide group.

149 istage meta-analysis for lumbar spine (LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral dens

150 Patients who had total hip/knee replacement were enrolled.

151 95% confidence interval [CI], 3.5%-4.3%) and total hip (mean change, 1.7% vs -0.1%; between-group dif

152 a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an inc

153 A-adjusted BMC at the whole-body, spine, and total hip of between 1% and 4%.

154 res, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral hernia repair, a

155 cacy and tolerability in patients undergoing total hip or knee arthroplasty.

156 Patients with RA who undergo total hip or knee replacement are at increased risk of p

157 included all patients with RA who underwent total hip or knee replacement at the Mayo Clinic Rochest

158 hylaxis against venous thromboembolism after total hip or knee replacement is uncertain.

159 Patients undergoing total hip or knee replacement or colorectal resections h

160 d 92 patients undergoing primary or revision total hip or knee replacement.

161 ance of young age and risk of revision after total hip or knee replacement.

162 Candidates for total hip or total knee arthroplasty were reviewed in a

163 T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of t

164 e spine, and had a 1.2% +/- 0.5% loss at the total hip (P < .05).

165 the decrease in bone mineral density in the total hip (P = 0.031), trochanter (P = 0.006), hip neck

166 bar spine (P<0.001), trochanter (P = 0.003), total hip (P=0.005), and trabecular bone of the lumbar s

167 sing dual-energy x-ray absorptiometry at the total hip, posterior-anterior spine, and total body; blo

168 t three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone

169 Total hip prostheses and spinal hardware that terminated

170 ral lumbar spine (r = 0.52, p < or = 0.001), total hip (r = 0.39, p = 0.01), total radius (r = 0.39,

171 resection ($63117 vs $21325; P < .001), and total hip replacement ($41354 vs $19028; P < .001).

172 07647), pulmonary resection (n = 91758), and total hip replacement (n = 307399) between 2009 and 2012

173 ABG) (218940 patients at 1056 hospitals), or total hip replacement (THR) (231774 patients at 1831 hos

174 Mortality and complication rates after total hip replacement (THR) are inversely associated wit

175 Total hip replacement (THR) is extremely common.

176 Implant survival after conventional total hip replacement (THR) is often poor in younger pat

177 Total hip replacement (THR) is successful in treating hi

178 ompared with patients undergoing an elective total hip replacement (THR) operation.

179 es the risk for venous thromboembolism after total hip replacement (THR) or total knee replacement (T

180 nd-stage hip osteoarthritis (OA) who undergo total hip replacement (THR) preferentially require subse

181 hyte score, decrease in MJS of > or =0.5 mm, total hip replacement (THR), and increase in lower extre

182 e rates in patients with hip OA undergoing a total hip replacement (THR), as compared with disease-fr

183 rates varied widely for patients undergoing total hip replacement (THR), colectomy, and pancreaticod

184 s, the progression of the disease required a total hip replacement (THR).

185 nter tenderness, hip pain or tenderness, and total hip replacement (THR).

186 h) and predictive validity (association with total hip replacement [THR] and signs and symptoms a mea

187 en concordant for primary OA (ascertained by total hip replacement [THR] or total knee replacement),

188 identified 63 158 patients who had undergone total hip replacement and 54 276 who had total knee repl

189 Among patients who had total knee or total hip replacement and received 4 to 10 days of posto

190 d rates of CABG, carotid endarterectomy, and total hip replacement in 158 hospital-referral regions (

191 imate the population requirement for primary total hip replacement in England.

192 dance on wisdom tooth extraction and primary total hip replacement in the UK National Health Service.

193 Total hip replacement is a commonly performed orthopedic

194 Death within 90 days after total hip replacement is rare but might be avoidable dep

195 quiring revision surgery in patients who had total hip replacement or total knee replacement over the

196 Practice Research Datalink who had undergone total hip replacement or total knee replacement.

197 In the 1960s, total hip replacement revolutionised management of elder

198 The Readmission After Total Hip Replacement Risk Scale was developed to predic

199 cation models, such as the Readmission After Total Hip Replacement Risk Scale, can identify high-risk

200 ey were used to create the Readmission After Total Hip Replacement Risk Scale, which was applied to t

201 rom a registry of patients who had undergone total hip replacement surgery over an 8-year period at a

202 The requirement for total hip replacement surgery was estimated on the basis

203 ndergone a primary or revision total knee or total hip replacement surgery.

204 if another family member also had undergone total hip replacement surgery.

205 For total hip replacement there was no significant change in

206 nical characteristics of patients undergoing total hip replacement were abstracted.

207 ervices dictate that further developments in total hip replacement will be governed by their cost-eff

208 proportion of male patients ranged from 37% (total hip replacement) to 77% (abdominal aortic aneurysm

209 en concordant for primary OA (ascertained by total hip replacement), were genotyped for 36 microsatel

210 For total hip replacement, 10-year implant survival rate was

211 als performing coronary artery bypass graft, total hip replacement, abdominal aortic aneurysm repair,

212 replacement, 214 patients who had undergone total hip replacement, and 520 controls from the UK.

213 y, other comorbidity, admission FIM ratings, total hip replacement, and time to followup.

214 suggests that the satisfaction of demand for total hip replacement, given agreed criteria for surgery

215 ity, comorbidity, admission FIM ratings, and total hip replacement, OA was associated with a longer r

216 endarterectomy, reduction of femur fracture, total hip replacement, total knee replacement, partial c

217 es who underwent future targeted procedures (total hip replacement, total knee replacements) or nonta

218 grafting (CABG), carotid endarterectomy, and total hip replacement.

219 ere concordant for hip OA, as ascertained by total hip replacement.

220 lulare, septic wrist, bacteremia, and septic total hip replacement.

221 s had a total knee replacement and 825 had a total hip replacement.

222 eral elective surgical treatments, including total hip replacement.

223 sk for minor bleeding in patients undergoing total hip replacement.

224 that strongly associate with osteoarthritis total hip replacement: a missense variant, c.1141G>C (p.

225 ted with increased risk of readmission after total hip replacement: being older than 71 years (OR, 1.

226 knee replacements (TKRs), and 537 women with total hip replacements (THRs) from the Nottingham case-c

227 nce challenges the increasing trend for more total hip replacements and total knee replacements to be

228 performed a genome-wide association study of total hip replacements, based on variants identified thr

229 r the lateral spine, and 47% and 16% for the total hip, respectively.

230 ts had significantly reduced BMD z-scores at total hip, spine, and WB.

231 apparent for spine fractures (P = 0.02) and total hip, spine, and wrist fractures (P = 0.02).

232 neral density screening revealed osteopenia, total hip T score of -1.8.

233 ed zoledronic acid when lumbar spine (LS) or total hip (TH) T score decreased to less than -2.0 or wh

234 6%, 0.97%, I(2): 0%; n = 5) but no effect on total hip (TH), femoral neck (FN), or total body BMD or

235 significantly higher BMD and z scores at the total hip than did nontanners.

236 D by dual-energy x-ray absorptiometry at the total hip through month 12 (mean of months 6 and 12), wh

237 Increases in BMD were also observed at the total hip, total body, femoral neck, and the predominant

238 the mean annualized rate of bone loss at the total hip was -0.66% per year (95% confidence interval -

239 Loss of BMD at the femoral neck and total hip were also similar between treatment groups.

240 for the total-body radius, lumbar spine, and total hip were observed between subjects who received th